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314 The Journal of Thoracic and Cardbjective: Reliable platelet function monitoring is desirable in patients treated with
lycoprotein IIb/IIIa receptor inhibitors. The aim of the present laboratory-based
tudy was to assess platelet function after administration of clinically relevant doses
f the glycoprotein IIb/IIIa antagonist tirofiban with or without heparin by using
onoclot (Sienco Inc) and platelet aggregometry.
ethods: Tirofiban (0-100 ng · mL1) and heparin (0 or 1 U · mL1) were added
o blood samples obtained from 20 healthy volunteers. Coagulation analysis was
erformed on citrated whole blood by using the Sonoclot analyzer. The glass
ead–activated test and the new glass bead test with heparinase were used. The
esults were compared with adenosine-5=-diphosphate–activated platelet aggregom-
try.
esults: Administration of tirofiban showed a similar increase of platelet inhibition
etected with the Sonoclot glass bead–activated test and glass bead test with
eparinase, as well as by means of aggregometry. Bias between the different
echniques was comparable; Spearman rank correlation was strong (glass bead–
ctivated test vs aggregometry:  0.823, P .001; glass bead test with heparinase
s aggregometry:   0.856, P  .001). After additional administration of heparin,
latelet inhibition was only comparable for the glass bead test with heparinase and
ggregometry, and the correlation coefficient remained unchanged for the glass bead
est with heparinase versus aggregometry (  0.878, P  .001). By contrast, the
lass bead–activated test showed a nearly complete platelet inhibition with a
ignificant bias compared with the glass bead test with heparinase and aggregom-
try. Correlation was weak for the glass bead–activated test versus aggregometry
  0.407, P  .004).
onclusions: When compared with platelet aggregometry, the glass bead–activated
est from Sonoclot reliably detects glycoprotein IIb/IIIa receptor inhibition with
irofiban in unheparinized whole blood. However, in heparinized blood the glass
ead test with heparinase is essential to accurately assess platelet function.
harmacologic inhibition of platelet glycoprotein (GP) IIb/IIIa receptors is
an established adjunct in the management of patients with acute coronary
syndromes and in patients undergoing percutaneous coronary interven-
ions.1 Tirofiban, an intravenously administered, short-acting, nonpeptide 
osine derivative, acts as a reversible and selective antagonist of the GP IIb/IIIa
eceptor. After a 30-minute infusion of the recommended dose, platelet aggre-
ation is inhibited more than 90%, whereas platelet function (PF) returns to
ear-baseline levels within 4 to 8 hours after discontinuing the infusion. Tiro-
ban is now increasingly used together with heparin because it has been shown
o improve outcome in patients with acute coronary syndrome by preventing the
ccurrence of acute cardiac ischemic events.2,3 However, on requiring emer-
iovascular Surgery ● June 2006
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ETency surgical revascularization or other diagnostic and
herapeutic interventions, these patients might be at an
ncreased risk for excessive bleeding.4-6 Some data indi-
ate that the risk of perioperative bleeding can be limited
y promptly stopping infusion of the GP IIb/IIIa inhibi-
ors before surgical intervention and by means of peri-
perative platelet transfusion,7-9 but discontinuing thes
ive-saving drugs might be harmful and should be
voided if possible.
Reliable bedside perioperative monitoring of both anti-
oagulant and PF is necessary to effectively manage the
esired hemostasis suppression and its reversal. One of the
ajor limitations of measuring PF has been that no reliable
ractical test exists. The historical gold standard, the bleed-
ng time test, is a very crude measurement technique of PF.
leeding time tests are poorly reproducible, invasive, in-
ensitive, and time consuming. Turbidimetric platelet ag-
regometry, a clinical standard to measure PF ex vivo,
equires specialized laboratory resources and is cumber-
ome to perform.10 A number of new testing methods h
ecently been developed to easily monitor PF at the patient’s
edside.11 One of these devices, the Sonoclot Coagulat
nd Platelet Function Analyzer (Sienco Inc) provides point-
f-care monitoring of the coagulation process from initial
brin formation through platelet activation and clot retrac-
ion.12 The Sonoclot analyzer has been shown to accura
ssess impaired PF.13 However, Sonoclot analyses wit
tandard activators are heparin sensitive, and the presence of
eparin might artificially modify the PF results. To over-
ome this problem, a new test containing glass beads and
eparinase has been developed for the Sonoclot analyzer:
lass beads are required for contact activation of the coag-
lation cascade, and heparinase is used to inactivate present
eparin.
The aim of this laboratory study was to evaluate the
tandard glass bead–activated test (GB) and a new glass
ead–activated test containing heparinase (hepGB) for the
Abbreviations and Acronyms
ACT  activated clotting time
CPB  cardiopulmonary bypass
GB  glass bead–activated test
GP  glycoprotein
hepGB glass bead–activated test containing
heparinase
PF  platelet function
PPP  platelet-poor plasma
PRP  platelet-rich plasmaonoclot analyzer in assessing PF and to compare these p
The Journal of Thoracicests with turbidimetric platelet aggregometry. Blood sam-
les were analyzed after addition of clinically relevant doses
f tirofiban and heparin in vitro.
ethods
ith institutional approval and written informed consent, 20
ealthy volunteers without hereditary or acquired coagulation dis-
rders (including pharmacologically induced coagulopathies; ie,
reatment with any anticoagulants or antiplatelet drugs 14 days
efore blood withdrawal) were included. Each volunteer donated
5 mL of blood, which was placed in citrated tubes (sodium
itrate, 0.109 mol · L1; BD Vacutainer, Becton Dickinson) by
eans of venipuncture. An initial Vacutainer tube was discarded
efore collection of the test samples. Baseline measurements in-
luded hemoglobin concentration, platelet count, prothrombin
ime, activated partial thromboplastin time, and celite-based acti-
ated clotting time (ACT).
Ten milliliters of citrated blood was used for whole blood
oagulation measurements (ie, Sonoclot analyses). Another 20 mL
f blood was processed for platelet aggregometry: the samples
ere centrifuged to obtain platelet-rich plasma (PRP; 135g for 15
inutes) and platelet-poor plasma (PPP; 2000g for 20 minutes).
PP was used to adjust the platelet count of PRP to within 10% of
aseline platelet count.
Tirofiban (Merck & Co, Inc) was added to the samples to
btain a final concentration of 0, 12.5, 25, 50, and 100
g · ml1. All samples were analyzed without and with porcine
eparin (Liquemin, Roche Pharma) in a final concentration of 1
· ml 1 (Figure 1).
onoclot Analysis
he Sonoclot analyzer is a point-of-care automated coagulation
nalyzer and has been described previously in detail.12,13
riefly, the measurement is based on the detection of viscoelas-
ic changes of a whole blood sample after activation with
ifferent coagulation activators (glass beads were used for this
tudy). The Sonoclot analyzer provides information on the
ntire hemostasis process both in a qualitative graph, known as
he Sonoclot signature (Figure 2, A ), and as quantitative result
CT (onset of clot formation), clot rate (maximum slope of the
onoclot signature during initial fibrin polymerization), and PF
timing and quality of clot retraction).12 PF is a calculate
alue, derived by using an automated numeric integration of
hanges in the Sonoclot signature after fibrin formation has
ompleted (see manufacturer’s reference). The nominal range
f values for the PF goes from 0, representing no PF (no clot
etraction and flat Sonoclot signature after fibrin formation), to
pproximately 5, representing strong PF (clot retraction occurs
ooner and is very strong, with clearly defined, sharp peaks in
he Sonoclot signature after fibrin formation). All Sonoclot
nalyses were performed at 37°C in duplicate by using standard
B (Sienco Inc) and hepGB (0.17 U of heparinase per test;
ienco Inc). Recalcification of the sample was done by adding
3 L of 0.25 mol · L1 CaCl2 to the test cuvette. Subse-
uently, 320 L of blood specimen was dispensed with a
ipette, mixed, and analyzed. In the present study, we used
and Cardiovascular Surgery ● Volume 131, Number 6 1315
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EToftware Version 2.0.3 (release 04/2002) from the Sonoclot
nalyzer.
latelet Aggregation
lood samples were centrifuged to obtain PRP and PPP, as de-
cribed above. Platelet aggregation was optically monitored by
sing a 2-channel turbidimetric platelet aggregometer (Sienco Inc).
hree hundred microliters of plasma was stirred in an aggregome-
er cuvette containing 20 mol · L1 adenosine-5=-diphosphate
Sigma Diagnostics). Measurements were performed at 37°C in
uplicate, and PRP aggregation was measured against PPP aggre-
ation. A baseline aggregation response (no tirofiban or heparin
resent) was determined for each donor. The percentage of aggre-
ation was determined at the point of maximum light transmission
btained within 5 minutes.
ata Analysis
tatistical analysis was done with StatView for Windows version 5.01
SAS Institute Inc) and SPSS for Windows Release 12.0.2 (SPSS
nc). The hypothesis of normal data distribution was rejected by using
he Kolmogorov-Smirnov test. Effects of different concentrations of
irofiban on PF determined by means of the GB test, the hepGB test,
nd aggregometry with and without heparin were determined by using
he Friedman test (repeated measurements). The Wilcoxon signed-
ank test was calculated to assess the effect of heparin on both
onoclot tests and aggregometry. The percentage of platelet inhibition
igure 1. Study overview. Sonoclot GB, Glass bead–activated
uvettes; Sonoclot hepGB, glass bead–activated cuvettes with
eparinase; Aggregometry, adenosine-5=-diphosphate–activated,
urbidimetric platelet aggregometry.as calculated by using the following formulas: t
316 The Journal of Thoracic and Cardiovascular Surgery ● JunPlatelet inhibitionSonoclot
 (Baseline platelet function
 Platelet function after tirofiban with or without heparin) ⁄
(Baseline platelet function) 100 (1)
% Platelet inhibitionAggregometry
 (% Baseline aggregation
% Aggregation after tirofiban with or without heparin) ⁄
(% Baseline aggregation) 100 (2)
Bias between the percentage of platelet inhibitionSonoclot and
he percentage of platelet inhibitionAggregometry was calculated as
he difference of the percentage of platelet inhibitionSonoclot (GB
nd hepGB tests) and the percentage of platelet inhibitionAggregometry.
he Wilcoxon signed-rank test and Spearman rank correlation were
sed to compare the percentage of platelet inhibition assessed by
he different testing methods. Test variability of duplicate mea-
urements was calculated as a percentage of the mean percentage
egree of platelet inhibition. Unless otherwise stated, nonparamet-
ic data are presented as median/interquartile range.
esults
aseline coagulation parameters of the 20 volunteers (mean
ge, 36 [SD, 8] years; female/male ratio, 8/12) were within
ormal ranges, mean hemoglobin value was 14.0 g · dL1
SD, 1.3 g · dL1), and mean platelet count was 244 
03 · mm3 (SD, 29  103 · mm3).
easurements Without Heparin
onoclot signatures from one representative patient are
hown in Figure 2, B, by using hepGB tests. The addition
irofiban in increasing concentrations led to a similar, sig-
ificant, and gradual decrease of PF assessed with the Sono-
lot analyzer by using GB and hepGB tests, as well as by
eans of aggregometry (Table 1). Accordingly, the ca
ated percentage of platelet inhibition showed a significant
tepwise increase for all 3 testing methods (Figure 3A).
he bias between the percentage of platelet inhibition as-
essed by using the Sonoclot analyzer (GB/hepGB tests)
nd the percentage of platelet inhibition measured by using
ggregometry was not significant and decreased with in-
reasing concentration of tirofiban (Figure 4, A). The bias o
he percentage of platelet inhibition between the GB test and
he hepGB test was 0.3/14.4% (mean [SD]  1.8
11.3%]; P  .162). There was a significant and strong
orrelation of the percentage of platelet inhibition assessed
y using the Sonoclot analyzer and aggregometry (Table
easurements After Addition of Heparin
fter administration of heparin (1 U · mL1), mean baseline
aolin ACT increased from 118 (SD, 23) to 280 (SD, 75)
econds. PF analysis showed comparable patterns with the
onoclot hepGB test and aggregometry for the 5 differentirofiban concentrations (Table 1 and Figure 3, B). Bias and
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ETorrelation for the percentage of platelet inhibition was com-
arable with the values obtained for measurements without
eparin (Figure 4, B, and Table 2). By contrast, assessm
ith the Sonoclot GB test without heparinase showed a nearly
omplete loss of PF after addition of tirofiban. A signi
ias of the percentage of platelet inhibition assessed with
onoclot GB test and aggregometry for all tirofiban con
igure 2. Sonoclot signatures. A, Typical Sonoclot signature. The
ollowing quantitative results are obtained: (1) activated clotting
ime (onset of clot formation); (2) clot rate (maximum slope of the
onoclot signature during initial fibrin polymerization), and (3)
latelet function (timing and quality of clot retraction). B, Sono-
lot signatures from one representative patient after administra-
ion of different concentrations of tirofiban to blood samples in
itro (final concentration  0, 12.5, 25, 50, and 100 ng · ml1).rations was observed (Figure 4, B). Bias of the percentage of r
The Journal of Thoracict
lat elet inhibition between the GB and hepGB tests was 
8.0% (mean [SD] 26.3 [22.1%]; P .001). Correlations of
he percentage of platelet inhibition comparing the GB with the
epGB test, as well as the GB test with aggregometry, were
eak (Table 2).
est Variability
n measurements without heparin, test variability (related to
he percentage of platelet inhibition) for the GB test was
.6/8.4% (mean [SD] 9.8 [9.5%]), for the hepGB test was
.0/8.9% (mean [SD]  8.3 [7.9%]), and for aggregometry
as 6.4/7.3% (mean [SD]  6.7 [5.3%]). The addition of
eparin induced a significant change of test variability for
he GB test (0.0/3.8%; mean [SD]  10.1 [27.9%]; P 
001), whereas test variability for the hepGB test and ag-
regometry remained unchanged (hepGB test  6.1/78.0%;
ean [SD]  8.4 [8.5%]; P  .717; aggregometry 
.0/9.1%; mean [SD]  7.4 [6.4%]; P  .197).
iscussion
n the present in vitro study, platelet inhibition with tirofi-
an was reliably monitored with the hepGB test in both
nheparinized and heparinized blood samples. The results
ith this hepGB test correlated well with those obtained
ith adenosine-5=-diphosphate–activated platelet aggregom-
try. By contrast, the GB test was only reliable to monitor
latelet inhibition by tirofiban in unheparinized blood samples.
Shorter-acting platelet GP IIb/IIIa inhibitors like tirofi-
an have become an increasingly important therapeutic op-
ion in unstable coronary artery disease, as well as during
nd after percutaneous coronary interventions.14 In patients
ith acute coronary syndrome, treatment with tirofiban
ombined with heparin has been shown to improve patients
utcome.2,3 However, platelet inhibition with GP IIb/I
nhibitors is not restricted to cardiac patients only. These
rugs are also used in other clinical situations in which
revention of an arterial thrombosis is a primary goal. For
xample, GP IIb/IIIa antagonists have been successfully
sed as an adjunct in thrombolysis management of periph-
ral arterial occlusions.15 Because GP IIb/IIIa inhibitor
mpair PF considerably, one might expect that excessive
leeding during surgical intervention or major interventions
ight occur if timing and dosing are not adequate. Indeed,
ome studies with the long-acting GP IIb/IIIa inhibitor
bciximab showed increased bleeding and transfusion re-
uirements if surgical intervention had been performed
ithin 12 hours of receiving this drug.16 However, the
ituation with the short-acting inhibitors tirofiban and epti-
batide is less clear. There are only a few case reports
escribing excessive intraoperative and postoperative hem-
rrhage after treatment with tirofiban or eptifibatide.4,5 Most
tudies showed either comparable or even reduced bleeding
ates in patients undergoing cardiopulmonary bypass (CPB)
and Cardiovascular Surgery ● Volume 131, Number 6 1317
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ETurgery.7,9 The question remains of whether short-acting 
Ib/IIIa inhibitors can inhibit platelet reactivity during CPB,
reventing platelet aggregation and adhesion and thus pre-
erving platelet number and function after CPB ends. Ac-
ording to this theory, the key requirement would be that the
F is completely inhibited before heparinization and that this
nhibition is quickly reversed after ending the CPB, allowing
dequate hemostasis (also called “platelet anesthesia”).17,18
Tirofiban is a reversible antagonist of fibrinogen binding
o the GP IIb/IIIa receptor, the major platelet surface recep-
or involved in platelet aggregation. When administered
ntravenously, tirofiban inhibits platelet aggregation in a
ose- and concentration-dependent manner. When adminis-
ered according to the recommended regimen, more than
0% platelet inhibition is attained by the end of a 30-minute
irofiban infusion. It has a half-life of approximately 2
ours, and it is cleared from the plasma largely by means of
enal excretion. In patients with atherosclerotic disease and
mpaired renal function, plasma clearance is significantly
ower. Pharmacokinetics are fairly predictable in healthy
atients, but this might not be the case in the typical patient
eceiving tirofiban. Furthermore, empiric dosing of GP IIb/
IIa antagonists on a body weight or surface area basis
ight be suboptimal because of known interpatient variabil-
ty19-21 based on variations of platelet count and the ab
f these platelets to aggregate. The goal of PF monitoring
uring treatment with GP IIb/IIIa antagonists is to confirm
dequate platelet inhibition and to possibly titrate the dose
ccording to individual needs. On the other side, PF mon-
toring should allow detection of unwanted platelet inhibi-
ion, such as prolonged action after discontinuing these
rugs in renal disease or CPB-related platelet dysfunctions.
ormal platelet count and preserved PF are required for
ABLE 1. Platelet function assessed with Sonoclot GB/he
Tirofiban
Sonoclo
GB PF
o heparin
0 ng · mL1 4.0/0.9 3.8 (0.6)
12.5 ng · mL1 2.6/0.9 2.5 (0.6)*
25 ng · mL1 1.6/0.7 1.5 (0.6)*
50 ng · mL1 0.8/0.6 0.9 (0.5)*
100 ng · mL1 0.3/0.3 0.4 (0.2)*
U · mL1 heparin
0 ng · mL1 1.0/1.8 1.2 (1.1)†
12.5 ng · mL1 0.1/1.3 0.5 (0.7)*†
25 ng · mL1 0.0/0.1 0.1 (0.3)†
50 ng · mL1 0.0/0.0 0.1 (0.1)†
100 ng · mL1 0.0/0.0 0.0 (0.1)†
ata are presented as median/interquartile range and mean (SD). GB, Gla
latelet function; Aggregometry, adenosine-5=-diphosphate–activated, tu
irofiban concentrations, †P  .05 for comparison of no heparin versus 1dequate perioperative hemostasis. In patients with acute a
318 The Journal of Thoracic and Cardiovascular Surgery ● Junoronary syndrome undergoing emergency cardiovascular
urgery or other major interventions, GP IIb/IIIa inhibitor
reatment is usually continued up until shortly before the
rocedure. Reliable bedside PF monitoring is highly desir-
ble for optimal coagulation management to prevent high
lood loss, which is related to impaired clinical outcom6
nd might result in better clinical outcome.19
Traditional assays, such as turbidimetric platelet aggre-
ometry, are still considered clinical standards of PF testing.
urbidimetric platelet aggregometry is one of the most
idely used tests to identify and diagnose PF defects. How-
ver, conventional platelet aggregometry is labor intensive,
ostly, time consuming, and requires a high degree of ex-
erience and expertise to perform and interpret. Another
mportant limitation of this technique is that platelets are
ested under relatively low shear conditions and in free
olution within PRP, conditions that do not accurately sim-
late primary hemostasis.11 Because of these disadvantage
f conventional platelet aggregometry, new automated tech-
ologies have been developed to measure PF, as described
reviously in detail.10,11,22 Several techniques can be us
t the bedside, such as ICHOR/Plateletworks (Helena Lab-
ratories; comparing platelet counts in whole blood within a
aseline EDTA tube and after activation/aggregation with
platelet agonist); PFA-100 (Dade Behring Inc; platelet
dhesion/aggregation measured under high shear conditions
n the presence of platelet activators), IMPACT (DiaMed
G; platelet adhesion/aggregation on a plate under applied
hear stress in whole blood), Ultegra-RPFA (Accumetrics
nc; modified turbidimetric platelet aggregometry in whole
lood), Mulitplate (Dynabyte GmbH; impedance platelet
ggregometry in whole blood), hemoStatus (Medtronic Inc;
F derived from measurement of the ACT in the presence or
cuvettes and platelet aggregometry
lyzer Platelet aggregometry
(%)hepGB PF
3.6/0.5 3.5 (0.6) 83.0/12.9 82.3 (8.6)
2.0/0.8 2.2 (0.6)* 58.0/15.3 59.1 (12.4)*
1.4/0.8 1.2 (0.5)* 35.5/8.5 37.4 (8.1)*
0.7/0.4 0.7 (0.3)* 14.5/6.3 16.4 (5.8)*
0.3/0.3 0.3 (0.2)* 10.0/2.8 9.5 (2.5)*
3.7/0.7 3.5 (0.7) 80.0/6.5 80.9 (6.8)
2.0/0.7 2.1 (0.7)* 59.8/19.5 57.1 (14.1)*
1.0/0.8 1.3 (0.7)* 33.8/11.8 34.6 (10.3)*
0.6/0.4 0.6 (0.3)* 15.8/5.3 16.9 (5.2)*
0.3/0.4 0.3 (0.2)* 9.0/5.0 8.3 (3.6)*
ad–activated test; hepGB, glass bead–activated test with heparinase; PF,
etric platelet aggregometry. *P  .05 for comparison of consecutive
L1 heparin.pGB
t ana
ss be
rbidimbsence of platelet-activating factor), Hemostasis Analysis
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ETystem (Hemodyne Inc; global hemostasis assessment in
hole blood, PF derived from the force generated by plate-
ets during clot retraction), thrombelastography/-metry
TEG 5000, Haemoscope Corp/ROTEM, Pentapharm GmbH;
lobal hemostasis assessment in whole blood, PF derived
rom maximal clot-shear elasticity), or the Sonoclot Coag-
lation and Platelet Function Analyzer.
In contrast to most other PF monitoring devices, the
onoclot analyzer provides bedside information on the en-
ire hemostasis process, including PF, and has been shown
o accurately assess impaired PF.13 In a clinical settin
nhibition of platelet aggregation with GP IIb/IIIa antago-
ists is usually combined with heparin to inhibit thrombin
eneration. Combining these 2 drugs has a summation ef-
ect on the coagulation inhibition. The presence of heparin
ill mask PF information by preventing platelet activation.
herefore displayed PF results for heparinized blood sam-
Figure 3. Percentage of platelet inhibition assessed by
no heparin; B, 1 U · mL1 heparin). GB, Sonoclot glas
activated cuvettes with heparinase; Aggregometry, a
aggregometry. *P < .05 for comparison of consecutive
heparin versus 1 U · mL1 heparin.les treated with antiplatelet drugs might be unreliable p
The Journal of Thoracicnless heparinase is present. Our data with the Sonoclot
nalyzer show that detection of PF inhibition with the
onventional GB test was only accurate in unheparinized
lood samples after treatment with tirofiban. However, the
ew test containing glass beads and heparinase (hepGB)
erformed well in both unheparinized and heparinized
lood samples. Heparinase enzymatically inactivates hepa-
in in the sample so that PF can be adequately assessed. The
epGB test is designed for blood samples with therapeutic
eparin levels (0.6  0.3 U · mL1) because the amount of
eparinase in the test tube is able to immediately neutralize
t least 1 U · mL1 of heparin.
The Sonoclot analyzer has been criticized because its results
ere influenced by age, sex, and platelet count.23 Additionally,
tudies showed poor reproducibility of some of the measured
arameters, especially clot rate and PF.22,24 However, others
ound the Sonoclot analyzer to be valuable and reliable in
g the Sonoclot analyzer and platelet aggregometry (A,
ad–activated cuvettes; hepGB, Sonoclot glass bead–
sine-5=-diphosphate–activated, turbidimetric platelet
fiban concentrations, §P < .05 for comparisons of nousin
s be
deno
tiroatients undergoing cardiac surgical procedures,13,25 and the
and Cardiovascular Surgery ● Volume 131, Number 6 1319
Evolving Technology Tucci et al
1
ETFigure 4. Bias of the percentage of platelet inhibition assessed by using the Sonoclot analyzer and platelet
aggregometry (A, no heparin; B, 1 U · mL1 heparin). GB, Sonoclot glass bead–activated cuvettes; hepGB, Sonoclot
glass bead–activated cuvettes with heparinase; Aggregometry, adenosine-5=-diphosphate–activated, turbidimetric
platelet aggregometry; IQR, interquartile range; SD, standard deviation. Bias is defined as the percentage of
platelet inhibition assessed with the Sonoclot analyzer minus the percentage of platelet inhibition measured by
means of platelet aggregometry. #P< .05 for comparison of the percentage of platelet inhibition assessed with the
Sonoclot analyzer and the percentage of platelet inhibition measured by means of platelet aggregometry.
320 The Journal of Thoracic and Cardiovascular Surgery ● June 2006
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ETonoclot analyzer has even demonstrated a precision close to
hat of thrombelastography.26 In the present study we w
ble to show reliable results with reproducibility comparable
ith that of turbidimetric platelet aggregometry. One possible
xplanation for this better performance might be the different
ests used in our study (GB and hepGB) compared with those
sed in earlier publications (predominantly testing of celite-
ctivated blood samples).
The present study has some limitations. An in vitro study
oes not necessarily reflect coagulation changes in vivo, and
he clinical relevance of impaired PF cannot be shown (eg,
leeding of the patient or the need for platelet transfusion). The
resent study was performed with blood samples of healthy
olunteers and administration of one GP IIb/IIIa antagonist (ie,
irofiban). Care should be taken to extrapolate these in vitro
esults to the in vivo surgical situation, as well as the results
btained with tirofiban to other GP IIb/IIIa antagonists. Further
tudies have to confirm our in vitro findings by using speci-
ens obtained from patients who are receiving these agents as
art of their clinical management. Additionally, we compared
esults from the Sonoclot analyzer (whole blood samples) with
esults from platelet aggregometry obtained in PRP. Coagula-
ion processes in PRP might not accurately reflect primary
emostasis in whole blood. However, platelet aggregometry in
RP is the clinical standard to assess PF and measures the
ercentage of platelets that aggregate on stimulation with a
latelet agonist. The Sonoclot analyzer does not measure PF
irectly but calculates PF from the quality of clot retraction.
urthermore, to compare results from the 2 measurement tech-
iques, we calculated the percentage of platelet inhibition. This
annot be calculated in most patients because no baseline PF
xists. In clinical practice the value given from the Sonoclot
nalyzer for PF gives an estimate of the current status, and
hange in PF over time can be monitored.
In conclusion, our in vitro data indicate that GP IIb/IIIa
nhibition with tirofiban is accurately reflected by the Sono-
ABLE 2. Spearman rank correlation coefficients compar-
ng the percentage of platelet inhibition assessed with
onoclot GB and hepGB cuvettes and platelet
ggregometry
Platelet
nhibition hepGB Aggregometry
o heparin
GB 0.892, P  .001 0.823, P  .001
hepGB — 0.856, P  .001
U · mL1
GB 0.385, P  .008 0.407, P  .005
hepGB — 0.878, P  .001
B, Glass bead–activated cuvettes; hepGB, glass bead–activated cuvettes
ith heparinase; Aggregometry, adenosine-5=-diphosphate–activated, tur-
idimetric platelet aggregometry.lot analyzer in the presence of heparin by using a heparinase-
The Journal of Thoracicontaining glass bead test (hepGB test). The standard glass
ead test (GB test), however, is only reliable in assessing PF
n situations in which no heparin is used.
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